Founded with a mission to revolutionize treatment for severe respiratory and chronic diseases, Aerami Therapeutics focuses on developing innovative inhaled therapies. The company aims to improve patient outcomes through advanced drug delivery systems, particularly targeting conditions like pulmonary hypertension. Aerami's core product pipeline includes AER-901, designed to optimize lung deposition and enhance therapeutic efficacy. Their market focus is primarily on patients with critical respiratory conditions who require more effective and convenient treatment options.

Aerami Therapeutics has garnered attention through significant presentations at major conferences such as the American Thoracic Society International Conference and CHEST. These events have highlighted their promising lung deposition modeling data and dosing regimens. The company’s leadership includes experienced professionals in respiratory medicine and drug development, supported by investors committed to advancing healthcare innovations. Aerami's impact lies in its potential to transform the management of debilitating respiratory diseases, offering hope for improved quality of life for affected patients.